ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
Aurobindo Pharma's subsidiary, Apitoria Pharma, incorporated a new wholly owned subsidiary named Avogent Lifesciences. The initial capital subscription for this pharmaceutical entity is Rs. 5 Crore.
Aurobindo Pharma incorporated a new wholly owned subsidiary, 'Auropharm Overseas Limited'. The company subscribed to the subsidiary's share capital of Rs. 0.1 Crore.
Aurobindo Pharma approved the merger of its wholly-owned step-down subsidiaries, Eugia Steriles and Eugia SEZ, into its wholly-owned subsidiary, Eugia Pharma Specialities, to simplify the group structure.
Aurobindo Pharma's subsidiary, Apitoria, will acquire an 80% stake in A1 Biochem Group for USD 13.6 Million to bolster its contract research and manufacturing capabilities.
Aurobindo Pharma Ltd created a new wholly‑owned subsidiary, PT Auro Pharm Indonesia, acquiring it for Rs.10.58 Crore cash. The step‑down subsidiary completes the incorporation on July 9 2026.
Aurobindo Pharma disclosed its subsidiary PT Aurogen Pharma Indonesia has created PT Auro Pharm Indonesia, subscribing cash of IDR 20 billion. The unit will manufacture in Indonesia.
Aurobindo Pharma USA Inc. completed the acquisition of Lannett Company LLC for ₹2,185 Crore. The deal adds Lannett's assets to Aurobindo’s portfolio.
Aurobindo Pharma USA Inc completed the acquisition of Lannett Company, making it a wholly‑owned subsidiary. The deal expands the group's capabilities in essential medicines.
Aurobindo Pharma completed the acquisition of a 26% stake in Swarnaaskshu Solar Power for Rs.0.52 Crore. The deal secures solar power under Telangana's captive policy.
Aurobindo Pharma acquired a 26% stake in Swarnaakshu Solar Power. The investment is valued at Rs.10.40 Crore.
Aurobindo Pharma's step-down subsidiary incorporated Arrow Pharma Production SAS in France. The new ₹1.11 Crore entity will expand generic formulation manufacturing operations.
Aurobindo Pharma Limited announced a share buyback of up to 5,423,728 equity shares via a tender offer at ₹1,475 per share. The total buyback size is ₹800 Crore. The record date is April 17, 2026, with the offer opening on April 23 and closing on April 29, 2026.
Aurobindo Pharma Limited announced a share buyback via tender offer for up to 5,423,728 shares at ₹1,475 each. The total consideration is capped at ₹800 Crore. The buyback opens on April 23, 2026, and closes on April 29, 2026, with promoters intending to participate.
Aurobindo Pharma Limited has submitted a Letter of Offer for the buyback of up to 54,23,728 equity shares at ₹1,475 per share. The total buyback size is ₹800 Crore via the tender offer route. The offer opens on April 23, 2026, and closes on April 29, 2026, targeting a 0.93% reduction in outstanding shares.
Aurobindo Pharma announced a buyback of up to 54,23,728 equity shares at ₹1,475 per share, totaling ₹800 Crore. The buyback will be conducted on a proportionate basis via the tender offer route for eligible shareholders as of the April 17, 2026 record date.
Aurobindo Pharma approved the slump sale of its domestic branded generic formulations business to its subsidiary, Auropharm Limited, for ₹143.21 Crore. The transaction aims to streamline operations and accelerate domestic growth. Completion is expected within 120 days, with economic benefits effective from April 1, 2026.